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Abstract
Background: Lipoprotein lipase (Lpl) acts on triglyceride-rich lipoproteins in the peripheral circulation, liberating free fatty
acids for energy metabolism or storage. This essential enzyme is synthesized in parenchymal cells of adipose tissue, heart,
and skeletal muscle and migrates to the luminal side of the vascular endothelium where it acts upon circulating
lipoproteins. Prior studies suggested that Lpl is immobilized by way of heparan sulfate proteoglycans on the endothelium,
but genetically altering endothelial cell heparan sulfate had no effect on Lpl localization or lipolysis. The objective of this
study was to determine if extracellular matrix proteoglycans affect Lpl distribution and triglyceride metabolism.
Methods and Findings: We examined mutant mice defective in collagen XVIII (Col18), a heparan sulfate proteoglycan
present in vascular basement membranes. Loss of Col18 reduces plasma levels of Lpl enzyme and activity, which results in
mild fasting hypertriglyceridemia and diet-induced hyperchylomicronemia. Humans with Knobloch Syndrome caused by a
null mutation in the vascular form of Col18 also present lower than normal plasma Lpl mass and activity and exhibit fasting
hypertriglyceridemia.
Conclusions: This is the first report demonstrating that Lpl presentation on the lumenal side of the endothelium depends
on a basement membrane proteoglycan and demonstrates a previously unrecognized phenotype in patients lacking Col18.
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Introduction
Heparan sulfate proteoglycans present in basement membranes
aid in the formation of tissue barriers and facilitate cell adhesion and
migration during development [1]. The major basement membrane
heparan sulfate proteoglycans include collagen XVIII (Col18) and
perlecan found ubiquitously in the vascular basement membrane
zones of tissues, and agrin, a critical component of the neuromuscular
junction basement membrane [2,3,4]. Systemic loss-of-function
alleles in perlecan and agrin are lethal in mice [5,6,7]. In contrast,
Col18-deficient mice (Col18a12/2) are viable but exhibit major
ocular defects including abnormal retinal vessel development and
poor anchoring of vitreal collagen fibrils to the inner lining membrane
of the retina [8,9,10]. Col18-deficiency also leads to increased
vascular permeability of large and small blood vessels and thickening
of basement membranes in the heart, kidney, and skin [9,11].
Lipoprotein lipase (Lpl) hydrolyzes triglycerides in triglyceride-
rich lipoproteins in the circulation, liberating free fatty acids and
monoacylglycerol for storage and energy production. This
essential enzyme is synthesized in parenchymal cells of adipose
tissue, heart, and skeletal muscle and migrates to the luminal side
of the vascular endothelium where it acts upon circulating
lipoproteins [12]. Recent studies indicate that Lpl is tethered to
the lumenal side of vascular endothelium by Gpihbp1, a protein
found on the surface of endothelial cells in the adipose, heart, and
skeletal muscle [13,14]. Genetic ablation of Gpihbp1 reduces
vascular presentation of Lpl and plasma levels of Lpl activity and
mass, which causes striking hypertriglyceridemia. Injection of
heparin releases Lpl into the circulation and rescues the
hyperlipidemic phenotype in Gpihbp1-deficient mice; however,
both Lpl release and the subsequent decline of plasma triglycerides
occur more slowly in the mutant compared to wild-type animals
[15]. These results suggest that Lpl is stored in a subendothelial
compartment awaiting transport. Recent findings demonstrate
that Gpihbp1 also facilitates the transport of Lpl from subendo-
thelial compartments to the lumenal side of the vasculature [14].
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Lpl binds to heparin, suggesting that it might associate with
heparan sulfate that is covalently attached to extracellular matrix
or cell surface proteoglycans [16,17]. Mutations in lipoprotein
lipase that impair heparin-binding reduce enzyme stability and
causes abnormalities in lipid delivery to tissues [18]. However,
genetically altering heparan sulfate selectively in endothelial cells
does not affect plasma levels of Lpl or lipolysis [15], consistent with
the hypothesis that the heparin-binding site of Lpl also interacts
with acidic domain in Gpihbp1 [19]. In this work, we found that
deletion of the heparan sulfate proteoglycan Col18 resulted in
reduced vascular Lpl mass and activity in mice and caused mild
hypertriglyceridemia, suggesting that the relevant Lpl-heparan
sulfate proteoglycan interaction occurs in the subendothelial space.
In contrast, mutant mice lacking the heparan sulfate attachment
sites in perlecan (Hspg2D3/D3) did not have mild hypertriglyceri-
demia. These findings are of clinical relevance because we show
that patients lacking the primary vascular form of Col18
(Knobloch Syndrome, OMIM 267750) also exhibit fasting
hypertriglyceridemia and decreased plasma Lpl, previously
unrecognized phenotypes in these patients.
Results
Col18-deficiency causes hypertriglyceridemia in mice
To investigate the possibility that sub-vascular heparan sulfate
proteoglycans participate in lipoprotein metabolism, we examined
Col18a12/2 mice and Hspg2D3/D3 mutant mice that lack the
heparan sulfate attachment sites in the basement membrane
proteoglycan, perlecan [20]. Col18a12/2 mice [8] had elevated
plasma triglycerides compared to wild-type littermate controls
(Fig. 1A) (65613 mg/dl in control mice vs. 119625 mg/dl in
mutants, n = 10, P,0.0001). These values did not vary signifi-
cantly according to the duration of fasting (4–8 hr), age of the
animals (2–12 months) or their sex. Plasma cholesterol levels were
slightly lower in mutants, but the difference did not achieve
statistical significance (Fig. 1B) (132617 mg/dl in wild type vs.
115624 in mutants, n = 10, P=0.101). Col18a1+/2 heterozygotes
did not display any changes in plasma lipids compared to the wild-
type controls (data not shown). In contrast to Col18a12/2 mice,
Hspg2D3/D3 mice did not exhibit any change in fasting plasma
triglycerides and cholesterol compared to wild type (plasma
triglycerides, 44615 mg/dL, n= 11 vs. 4864 mg/dL, n= 12;
plasma cholesterol levels, 6968 mg/dL vs. 7163 mg/dL),
consistent with the studies in Hspg2D3/D3 apoE2/2 mutants by
Tran-Lundmark et al [21].
Analysis of the plasma lipoproteins in fasted Col18a12/2
animals by LipoSEARCH profiling, which uses curve fitting
algorithms to gel filtration profiles to determine the relative
amounts of lipoprotein subclasses, showed that the mutant
accumulated large diameter particles corresponding in size to
chylomicron remnants and VLDL lipoprotein subclasses (Fig. 1C).
Electron microscopy showed significant enrichment of large
diameter lipoproteins in the mutant (.50 nm, Fig. 1D). The
plasma triglycerides floated at a d,1.006 g/ml (Fig. 1E), and
contained apolipoprotein B-100 (apoB-100), apolipoprotein B-48
(apoB-48) and apolipoprotein E (apoE) by western blotting
(Fig. 1F), consistent with their identification as VLDL or chylo-
micron remnants.
Delayed lipolysis in Col18a12/2 mice
To determine if turnover of dietary lipids was affected, we
examined the rate of lipoprotein clearance after oral gavage with
corn oil containing [3H]retinol, which is converted into fatty
acylated retinyl esters and packaged into chylomicrons. After
2 hours, plasma levels of [3H]retinyl esters were elevated .2-fold
in Col18a12/2 mice compared to wild-type animals and remained
elevated for 4 hours (Fig. 2A). Thereafter, the rate of disappear-
ance of 3H-retinyl ester counts was similar to that observed in wild-
type mice. Plasma triglycerides essentially paralleled the retinol
clearance curves over the same time course (data not shown).
Further analysis of plasma lipoproteins 2 hrs after gavage showed
that the majority of the triglycerides and [3H]retinol counts were
recovered in the large buoyant lipoproteins of d,1.006 g/ml (data
not shown). These lipoproteins were larger (.100 nm in diameter,
Fig. 2B) when compared to samples obtained from wild-type mice,
suggesting a defect in the initial lipolysis of triglyceride-rich
lipoproteins in the circulation. The rates of triglyceride secretion,
measured after injection of Triton WR-1339, were similar in the
wild type and mutant (0.03260.001 mg triglyceride/min in wild
type vs. 0.03260.004 mg triglyceride/min in mutant; n = 3,
P=1.0) [22], excluding a defect in chylomicron assembly or
secretion from the intestine.
To further examine early events in lipoprotein processing, we
measured the initial turnover of triglycerides injected intravenous-
ly in the form of Intralipid particles containing [3H]triolein, which
are proposed to resemble chylomicrons [23]. The initial loss of the
counts from the plasma was delayed in the mutant (Fig. 2C).
Fitting the data to a single exponential decay function yielded
fractional clearance rates of 3.2%60.5/min for the wild type
(R2 = .96) and 2%60.5/min (R2= 0.88) for the mutant. In
contrast to these findings, hepatic clearance appeared to be
normal in Col18a12/2 mice based on clearance of intravenously
injected human VLDL (Fig. 2D). Similarly, the rate of clearance of
[3H]retinol-labeled chylomicrons at later time points was compa-
rable in mutant and wild type (Fig. 2A). Together these data
suggest that the hepatic clearance of chylomicrons and VLDL was
normal in the mutant. Note that mutants lacking the transmem-
brane heparan sulfate proteoglycan, syndecan 1, or hepatocyte
sulfotransferases involved in heparan sulfate assembly develop
hypertriglyceridemia due to defects in hepatic clearance of
remnant particles [24,25,26]. In contrast, Col18a12/2 mice
develop hypertriglyceridemia due to altered extrahepatic clearance
triglyceride-rich lipoproteins.
Lpl expression and activity are normal in Col18a12/2
mice
The delayed lipolysis of plasma triglycerides in Col18a12/2 mice
could reflect deficiencies in various factors involved in Lpl-
mediated turnover, including angiopoietin-like 4 [27], caveolin-1
[28], and apolipoprotein C-II [29]. However, expression of these
proteins in skeletal muscle and adipose tissue were unaffected in
mutant compared to wild-type mice as measured by qPCR and
western blotting (data not shown). Furthermore, Lpl transcripts
and proteins in adipose, heart, and muscle tissue were unaffected
in both fasted (data not shown) and fed animals (Fig. 3A). Lpl
activity in tissue extracts was somewhat higher in mutant vs. wild-
type tissues; however, the differences did not reach statistical
significance (heart: 16006300 mU activity/g tissue in wild-type
mice vs. 19006500 in mutants, n = 3, P=0.53; adipose:
4868 mU activity/g tissue in wild-type mice vs. 65615 in the
mutant, n = 3, P=0.16). Recent studies indicate that Lpl is
localized to the vascular endothelium, bound to its receptor,
Gpihbp1 [14], suggesting the possibility that Lpl was mislocalized
in the mutant. However, immunolocalization studies showed that
Lpl distribution was not detectably altered in skeletal muscle from
Col18a12/2 mice and colocalized with the blood endothelial cell
marker, CD31 (Fig. 3B). The distribution of Lpl was also unaltered
in the heart (see below).
Col18 and Hyperchylomicronemia
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Figure 1. Hypertriglyceridemia in fasted Col18a12/2 mice. (A) Retro-orbital sinus blood was taken from wild-type and Col18a12/2 mice after
fasting the animals for 4 hrs in the morning. Total plasma triglycerides were compared between mutant and wild-type (n = 10 mice, unpaired t-test,
P,0.0001) and results were repeated. (B) Plasma cholesterol was analyzed in the same samples. (C) Triglyceride distribution across plasma
lipoprotein subclasses. Plasma was pooled from 4 mice of each genotype and triglycerides in lipoprotein size classes were determined by
LipoSEARCH FPLC. Control mice, filled bars; Col18a12/2 mice, open bars. Chylomicron (CM) .80 nm particle diameter; VLDL, 30–80 nm; LDL,
16–30 nm; and HDL, 8–16 nm. The experiment was performed twice and the error bars represent the range in the recovery of triglycerides in the two
experiments. (D) Equal volumes of lipoproteins of d,1.006 g/ml (pooled from n= 3 mice of each genotype) were analyzed by negative staining
transmission electron microscopy (inset, 20,0006magnification, bar = 50 nm). The diameters of particles present in eight fields were analyzed in a
blinded fashion. The experiment was repeated twice with comparable results. (E). The fraction of fasting lipoproteins of d,1.006 g/ml from Col18a1
mutants contained .4-fold more triglyceride than in wild type. The experiment was performed on pooled plasma samples from n= 4 mice and
repeated three times. (F) Equal volumes of d,1.006 g/ml lipoproteins were concentrated by membrane filtration and apolipoproteins were resolved
by gradient SDS-PAGE, then visualized by Western blotting with rabbit anti-mouse apolipoprotein B-48/B-100 and apolipoprotein E (apoE) polyclonal
antibodies.
doi:10.1371/journal.pone.0013919.g001
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To test if Lpl could be mobilized in the mutant, animals were
intravenously injected with 0.5 U of heparin. Twenty minutes after
injection, plasma Lpl levels were comparable in mutant and wild-
type mice (Fig. 4A; P=0.7). The time course of release of Lpl was also
comparable (Fig. 4B). Furthermore, heparin administration resulted
in the rapid disappearance of plasma triglycerides in Col18a12/2 and
wild-type mice under fasting conditions (Fig. 4C) as well as in mice
challenged orally with corn oil (Fig. 4D). Thus, the mobilization of
Lpl was normal in the mutant and the triglyceride-rich lipoproteins
that accumulated under fasting and post-prandial conditions were
fully capable of undergoing lipolysis when exposed to Lpl.
Lumenal Lpl is reduced in Col18a12/2 mice
Reduced presentation of Lpl at the lumenal side of capillaries
could explain the phenotype of Col18a12/2 mice [30]. To explore
this possibility, we injected mice with Intralipid, which unlike
heparin displaces only Lpl bound to the luminal surface of the
endothelium [15,31]. In wild-type mice, Intralipid induced the
release of Lpl into the plasma (Fig. 5A), albeit at much lower levels
than heparin (Fig. 4A). In contrast, mutant mice did not exhibit
any significant increase in plasma Lpl after injection. After
correction for the normal plasma pool of Lpl, the areas under the
curves showed a dramatic difference in displaceable enzyme in the
mutant (75 ng/ml in wild type vs. 8.2 ng/ml in mutant, n=8 in
two separate experiments). Since Lpl is rapidly cleared in the liver
[32,33], this technique may underestimate the amount of Lpl
bound to the endothelium; nevertheless, the levels are significantly
lower in Col18a12/2 mice compared to wild-type mice.
Inspection of the curves in Fig. 5A showed that the baseline level
of plasma Lpl (t = 0) was lower in the mutant. To avoid any effect
Figure 2. Characterization of hyperchylomicronemia in Col18a12/2 mice. (A) Chylomicron clearance assessed by retinyl ester excursion.
Fasted wild-type (closed circles, n=4) and Col18a12/2mice (open circles, n=4) were given 200 ml of corn oil containing [3H]retinol by oral gavage. Blood
samples were taken at the indicated times and radioactivity in 10 mL of serum was determined by scintillation counting in triplicate. The values are
expressed as mean 6 SD and are representative of three separate experiments. (B) Equal volumes of d,1.006 g/ml lipoproteins were purified from
plasma collected from n=3 mice of each genotype at 2 hrs post gavage, which corresponded to the time when the difference in [3H]-retinyl esters were
maximal between Col18a12/2 and wild-type mice. The d,1.006 g/ml lipoproteins were negative-stained and imaged by electron microscopy (20,0006
magnification) and, the diameters of all particles in 8 fields were measured in a blinded fashion. The percentage of lipoproteins .100 nm in diameter
were 2.8-fold increased in Col18a12/2 compared to wild-type mice. (C) [3H]Intralipid particles were injected intravenously in Col18a12/2 mice (open
circles, n = 3) and wild-type mice (closed circles, n = 3) and blood was drawn from the retro-orbital sinus at the indicated time. Results are expressed as
the percentage of cpm recovered after injection and are representative of two separate experiments. (D) Turnover of VLDL was measured in Col18a12/2
mice (open circles, n = 4) compared to controls (closed circles, n = 4). Human VLDL was injected intravenously and blood was drawn from the retro-
orbital sinus at the indicated times. Human apoB-100 was measured by ELISA using MB47, which binds human but not murine apoB-100, exactly as
described in [24]. Results are expressed as a percentage of the injected dose. The values are representative of two separate experiments.
doi:10.1371/journal.pone.0013919.g002
Col18 and Hyperchylomicronemia
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of preparing the animals for injection, we analyzed Lpl levels in
plasma of naive animals. As shown in Fig. 5B, the steady-state level
of plasma Lpl was much lower in the mutant (564 ng of Lpl/mL
in the mutant vs. 2464 ng Lpl/mL in the wild type, P=0.006).
Attempts to measure enzyme activity in the plasma were not
successful because the signal-to-noise ratio for the assay was not
sufficient, even after enrichment of plasma samples by heparin-
Sepharose chromatography.
Mice lacking Gpihbp1 also have markedly reduced amounts of
lumenally-exposed Lpl [14], suggesting the possibility that
Gpihbp1 expression might be reduced in Col18a12/2 mice.
However, transcript levels of Gpihbp1 were comparable in mutant
and wild-type mice in adipose, heart, and muscle (Fig. 6A). Flow
cytometric analysis of freshly isolated cardiac endothelial cells
using an anti-mouse Gpihbp1 antibody showed no difference in
expression (Fig. 6B). Furthermore, confocal microscopy demon-
strated that Gpihbp1, Col18 and Lpl have a similar vascular
distribution pattern in cardiac tissue sections of Col18a12/2 and
wild-type mice (Fig. 6C). However, the distribution of Lpl was
mislocalized in Gpihbp12/2 mice as recently reported [14].
Hypertriglyceridemia occurs in Knobloch patients lacking
the vascular form of Col18
The hypertriglyceridemia and reduction in plasma and endo-
thelium-bound Lpl in Col18a12/2 mice prompted further
evaluation in humans with Col18-deficiency. In humans, loss of
function mutations in COL18A1 cause Knobloch syndrome
(OMIM 267750). This extremely rare disorder is characterized
primarily by ocular defects, including myopia, vitreoretinal and
macular degeneration, retinal detachments, and occipital enceph-
alocele defects thought to arise from altered basement membrane
structures [34,35,36,37,38,39,40]. Several of the ocular defects are
similar to defects observed in Col18a12/2 mice [8].
A large consanguineous family of Knobloch patients was
identified in a remote farming community in Bahia State, Brazil
[39]. Linkage analysis studies showed that this family carries a null
mutation predicted to disrupt specifically the NC11-303 isoform
(short) of COL18A1 common to vascular basement membranes,
which is distinct from a long form splice variant expressed
abundantly in the liver and heart and regulated by a different
promoter [41]. Although small in number, the members of this
rare family constituted an ideal study group to test if a more
specific deficiency in vascular Col18 might give rise to elevated
plasma triglycerides as well. Normal, heterozygous, and homozy-
gous individuals had similar diets, shared living quarters, and were
selected with similar ages. Plasma cholesterol, glucose, and
triglyceride levels in plasma samples taken from seven Knobloch
patients were compared to six heterozygous carriers of the
mutation and seven normal controls (see Methods for study
inclusion criteria Supplemental Table S1). Fasted plasma triglyc-
erides were elevated to .200 mg/dl in 6 of 7 affected Knobloch
patients compared to ,150 mg/dl in unaffected family members
(P,0.05), but no significant difference was noted in heterozygotes
compared to normal or affected subjects (Fig. 7A). Ultracentrifuge
separation and analysis showed that the triglycerides accumulated
in lipoproteins of d,1.006 g/ml (data not shown). Plasma
cholesterol was elevated slightly, but the difference did not achieve
statistical significance with the limited number of individuals. One
of the patients (F1020-36, Supplemental Table S1) was borderline
diabetic (blood glucose = 130 mg/dl) in a field measurement, but
was euglycemic when tested again at a later time by colorimetric
assay. Thus, the hypertriglyceridemia seen was not due to diabetes
or other diseases that were diagnosed by their attending physician.
A single plasma sample from another Knobloch patient from the
same family, who was not included in Table S1 but lived in Sao
Paulo, Brazil, was compared to four unaffected household
members with similar results (plasma triglycerides 529 mg/dl in
the affected patient vs. 232648 mg/dl in controls, n = 4).
Finally, fasting plasma samples from Knobloch, heterozygous
and normal control related family members were compared for
differences in Lpl mass and activity levels. Results demonstrated
that the plasma levels of LpL enzyme in Knobloch subjects were
reduced compared to related heterozygous and normal control
family members (Fig. 7B, 3163 ng/ml for Knobloch patients,
5068 for heterozygotes, P,0.01; and 51.4615 for normal family
members, P,0.01). Unlike mouse plasma, human plasma had
sufficient Lpl activity to measure reliably. Knobloch patients also
exhibited reduced plasma Lpl activity (Fig. 7C, 1869 nmol
Figure 3. Lpl expression in Col18a12/2 mice. (A) Lpl mRNA was
measured by qPCR in samples prepared from gonadal fat pads, heart
and skeletal muscle from mutant and wild-type mice (n = 4 mice per
genotype). (B) Frozen tissue sections prepared from skeletal muscle
from wild-type and Col18a12/2 mice were stained with DAPI and
immunohistochemically stained for the endothelial marker CD31 and
Lpl. Samples were analyzed by confocal microscopy and compared for
differences in the distributions of CD31 (green) and Lpl (red). The
distributions of Lpl and CD31 overlap and are not altered in the
Col18a12/2 mutant. The images are from one set of samples, but the
experiment was repeated on four different mice.
doi:10.1371/journal.pone.0013919.g003
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triglycerides hydrolyzed/hr/ml; 101656 for heterozygotes,
P,0.05; and 1516101 for the wild type, P,0.01). The extreme
remote location of most family members and local dietary
restraints precluded other postprandial studies and interventions.
Discussion
This report demonstrates that Col18-deficiency results in
elevated plasma triglycerides and low plasma Lpl abundance
and activity. To our knowledge, this is the first demonstration of a
requirement for a specific extracellular matrix heparan sulfate
proteoglycan in triglyceride metabolism in vivo. This function was
unique to Col18 and not associated with perlecan, another
basement membrane heparan sulfate proteoglycan. Previous
studies showed that altering the expression of a specific
sulfotransferase involved in the formation of heparan sulfate
chains in hepatocytes and syndecan-1, a transmembrane heparan
sulfate proteoglycan, affected hepatic clearance of triglyceride-rich
lipoproteins [24,25,26]. In contrast, the defect in Col18a12/2 mice
appears to be due to reduced lipolysis of triglyceride-rich
lipoproteins in the peripheral circulation due to decreased
presentation of Lpl in the plasma compartment. Data supporting
this conclusion derive from the large size of triglyceride-rich
lipoproteins that accumulate in the mutant under fasting and
postprandial conditions, differences in the initial turnover of
[3H]retinol-labeled lipoproteins, and the lack of any effect on
hepatic turnover of remnant lipoproteins derived from dietary
triglyceride and injected human VLDL. Confirmatory evidence
was provided by studies of human Knobloch patients bearing a
mutation that affects the vascular short isoform of Col18.
How does a proteoglycan located in basement membranes affect
presentation of Lpl in the plasma and at the endothelial surface?
Lpl is secreted by the parenchymal cells of adipose, cardiac and
skeletal muscle and migrates from its site of secretion through the
Figure 4. Lpl in Col18a12/2 mice. (A) Wild-type and Col18a12/2 mice were injected intravenously with heparin (0.5 U/g body weight) and the
levels of Lpl in the plasma were measured 15 min later (n = 7 for each strain, P=0.7). Results are representative of two separate experiments. (B) Serial
sampling of plasma samples showed similar rates of appearance of Lpl after injection of 0.5 U/g heparin. (C, D) Plasma triglycerides were measured
pre- and post-heparin injection in wild-type and Col18a12/2 mice after (C) a 4-hour fast or (D) 2 hours after fat challenge. Heparin was injected
intravenously (0.5 U/g body weight) and blood was sampled from the retro-orbital sinus 10 minutes after injection. Results were verified in two
independent assays.
doi:10.1371/journal.pone.0013919.g004
Col18 and Hyperchylomicronemia
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interstitial space, across basement membranes and eventually the
endothelium [12]. Because Lpl contains one or more heparin binding
sites [17,42,43,44], it presumably can interact with the heparan
sulfate chains on Col18 or other matrix proteoglycans [10]. Binding
to Col18 could facilitate diffusion or protect Lpl during its transport
to the endothelial surface, perhaps in the same way that heparan
sulfate proteoglycans have been suggested to affect the rate of
diffusion or turnover of heparan sulfate-binding morphogens during
early development (e.g., Wnts, Hedgehog, FGFs, BMPs) [45,46,
47,48]. The inefficient presentation of Lpl could also reflect the
expansion and thickening of basement membranes that occurs in
various tissues (1.4 to 2-fold) due to Col18 deficiency [11]. A
quadratic relationship exists between time and distance for freely
diffusing molecules [49], therefore, small changes in distance could
greatly slow the rate of diffusion of Lpl. In either model, the delay in
transport could decrease the rate at which the active enzyme appears
in the blood compartment without significantly affecting total tissue
Lpl as measured by mobilization by heparin. Since Lpl is displaced
from Gpihbp1 by circulating triglyceride-rich lipoproteins and
rapidly cleared in the liver [15], a decrease in its rate of diffusion
through tissues could diminish the steady-state amount of active
enzyme bound to Gpihbp1 on apical endothelium and in the plasma.
Although simple in concept, proving this model has proven to be
difficult due to the absence of suitable in vitro models for measuring
transport through tissues and across vascular basement membranes.
Interestingly, the phenotype of Col18a12/2 mice resembles that
seen in mutants that affect Lpl expression or presentation. For
example, Lpl heterozygotes have reduced plasma levels of Lpl,
mild hypertriglyceridemia in both the fasted and post-prandial
states, and acute accumulation of plasma lipids after oral gavage
[50]. Gpihbp1-deficient animals also display decreased plasma Lpl
and Lpl associated with the endothelium (i.e. Lpl displaceable by
Intralipid) and injection of heparin raises plasma Lpl to the same
levels as the wild type [15]. However, Gpihbp12/2 mice differ
significantly from Col18a12/2 mice in the extent of hypertriglyc-
eridemia and localization of Lpl in tissues [14,15]. In Col18a12/2
mice, Lpl colocalized with CD31+ endothelium (Fig. 3), but it was
absent on the apical endothelium of brown fat capillaries of
Gpihbp12/2 mice, when the capillaries were viewed in cross-
section. The abundance of Lpl was not altered in Col18a1 mutants,
but it was increased in extracellular matrix that extended beyond
the distribution of endothelial and vascular basement membrane
markers in capillaries of Gpihbp1 mutants. Presumably these
differences reflect not only the amount of Lpl bound to the
endothelium, but also the rate at which it transfers from the
subendothelium to the lumenal side of the vasculature.
Recent large cohort clinical trials have shown that mildly
elevated triglycerides are a major risk factor for coronary heart
disease [51,52]. The work presented here shows that disruption of
Col18 in humans is associated with an increase in plasma
triglycerides, suggesting that decreased Col18 expression or
mutations affecting its heparan sulfate chains might account for
some cases of hypertriglyceridemia. For example, patients with
diabetes mellitus exhibit delayed metabolism of dietary triglycer-
ides in post-prandial studies [53,54]. The direct cause of
postprandial hyperlipidemia in these patients remains unknown,
but it is interesting to note that thickening of basement membranes
has been documented in the intima of the aorta as well as muscle,
glomerular and retinal capillaries in diabetes [55,56].
Methods
Mice and animal husbandry
Mice deficient in Col18 (Col18a12/2), and perlecan (Hspg2 D3/D3)
were described previously [8,9,10,57,58,59]. All mice were
backcrossed .10 generations on a C57Bl/6 background and
housed in vivaria approved by the Association for Assessment and
Accreditation of Laboratory Animal Care located in the School of
Medicine, University of California, San Diego, following standards
and procedures approved by the local Institutional Animal Care
and Use Committee (protocol S99127). Mice were weaned at 3
weeks, maintained on a 12 hr light-dark cycle, and fed ad libitum
with water and standard rodent chow (Harlan-TekLad) unless
indicated otherwise. Genotyping of Col18A12/2 was performed as
described [8].
Lipoprotein analysis
Plasma was prepared from retroorbital bleeds after fasting the
animals for 4 hr in the morning and plasma triglyceride and
cholesterol levels were determined enzymatically (Wako). Pooled
Figure 5. Pre-heparin plasma Lpl was reduced in Col18a12/2 mice. (A) Mice were injected intravenously with a bolus of Intralipid to mimic
hyperchylomicronemia and plasma Lpl was measured at the times indicated (n=4 for each strain; P,0.004). Results are representative of two
separate experiments. The areas under the curves were 75 ng/ml in wild type vs. 8.2 ng/ml in Col18a12/2 mice. (B) Plasma Lpl was measured by
sandwich ELISA in wild-type (black bars) and Col18a12/2 mice (white bars) (n = 7 for each strain; P= 0.006).
doi:10.1371/journal.pone.0013919.g005
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mouse plasma lipoproteins were also separated by gel filtration FPLC
(LipoSEARCH, Skylight Biotech Inc.). Plasma samples were
centrifuged for 20 hr at 45,0006 rpm in a Beckman 50.3Ti rotor
at d=1.006 g/ml to collect triglyceride-rich lipoproteins. Isolated
lipoproteins were dialyzed against PBS and analyzed for lipid content.
Electron microscopy
Lipoproteins of d,1.006 g/ml were purified from pooled plasma
obtained from fasted animals or after oral gavage of 0.2 ml corn oil
(n=3 or each genotype). To determine particle size, samples were
coded, negatively stained with 2% potassium phosphotungstate
(pH 7.6), and imaged by transmission electron microscopy (Jenny
Wong, Gladstone Institute). The diameters of particles in 8 fields were
measured, and the data from two separate experiments were pooled.
Triglyceride secretion rates in mice
Triglyceride secretion rates were determined by the method of
Hirano et al. [22]. Briefly Triton WR-1339 (500 mg/kg body
Figure 6. Normal vascular distribution of Gpihbp1 in Col18a12/2 mice. (A) mRNA expression was determined in RNA samples isolated from
gonadal fat pad, heart and soleus muscle from wild-type and Col18a12/2mice (n = 4, for each strain). Results were verified in two independent assays.
(B) Primary cardiac endothelial cells were isolated from control (solid line) and Col18a12/2 mice (dashed line) by collagenase digestion and magnetic
beads separations using anti-CD31 antibodies. Gpihbp1 was detected with a specific polyclonal antibody and Alexa-488 labeled anti-rabbit secondary
antibodies followed by FACS analysis. The curve to the left represents cells incubated with a control IgG and secondary antibodies. Data are
representative of 3 separate experiments. (C) Cardiac tissue sections from wild-type, Col18a12/2 and Gpihbp12/2 mice were analyzed by confocal
microscopy and compared for differences in the distributions of Lpl (red), Col18 (blue) and the Gpihbp1 (green). The distributions of Lpl and Gpihbp1
overlap with Col18 staining in wild-type heart tissues and are not altered in the Col18a12/2 mutant. The patterns of Lpl and Gpihbp1 staining were
unaffected in skeletal muscle and fat (data not shown).
doi:10.1371/journal.pone.0013919.g006
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weight, Sigma) was injected via the tail vein into mice fasted for
4 hr, and triglycerides were measured in plasma samples taken 30,
60, and 90 min post-injection. The secretion rate (mg/min) was
calculated from the increment in triglyceride concentration per
minute multiplied by the plasma volume of the mouse (estimated
as 0.035% of body weight in grams). To determine the intestinal
triglyceride secretion rate, Triton WR-1339 was injected into mice
that had been given a bolus of corn oil by gavage (0.2 ml/mouse).
VLDL, Intralipid, and retinol clearance
Clearance of human VLDL was performed by measuring the
level of human apoB-100 present in plasma at timed intervals
following intravenous injection of VLDL purified from fasted,
healthy human donors. Human apoB-100 was measured by
ELISA using mAb MB47, which binds human but not murine
apoB-100, exactly as described in [24]. [3H]triolein-labeled
Intralipid particles were made as described previously [23].
Samples (56105 cpm) were injected into the tail vein, blood
samples were taken at the indicated times, and radioactivity was
measured (10 ml of serum) by scintillation counting. Retinol
excursion studies were done essentially as described [60]. Briefly,
27 mCi of [11,12-3H]retinol (Perkin-Elmer, 44.4 Ci/mmol) in
ethanol was mixed with 1 ml of corn oil (Sigma) and administered
by oral gavage (200 ml/mouse). Blood was sampled at the times
indicated by retro-orbital sinus bleed and radioactivity was
measured in triplicate (10 ml of serum) by scintillation counting.
mRNA expression
Lpl and Gpihbp1 mRNA expression were determined in RNA
samples isolated from gonadal fat pad, heart and soleus muscle
from wild-type and Col18a12/2 mice (n= 4, for each strain). RNA
was isolated (10 mg/tissue, Trizol reagent), reverse transcribed
(Superscript III, Invitrogen) and amplified using gene specific
intron spanning primers to Lpl or Gpihbp1. Primer sequences,
Lpl, 59-AGGTGGACATCGGAGAACTG and 39- TTTGT-
CCAGTGTCAGCCAGA and, Gpihbp1, 59- AACATGATCC-
CTGGAAGCAG and 39- ACAGTGTGGACTGGCAACAG.
Quantitation was done by the 22DDCt method using b-actin as a
control RNA in a Stratagene MxP3500. Final numbers represent
fold-expression compared to b-actin (100%). Ct values from
triplicate assays were used to calculate fold-expression according to
Stratagene manual. Results were verified in two independent
assays.
Lipoprotein lipase activity and protein levels
Intravenous injection of heparin (0.5 U/g body weight) or 20%
Intralipid (7.5 ml/kg body weight) was used to release Lpl into the
plasma. Blood samples were taken by retro-orbital bleeding prior
to and at various times after injection. Lpl mass in plasma samples
was measured by ELISA with a specific antibody as described
previously [61].
Lpl activity in plasma or tissues was determined using sonicated
radiolabeled triolein substrate (tri[9,10(n)-3H]olein,,0.5 mCi/ml;
Perkin Elmer) and calculated as nmol triolein hydrolyzed per min
Figure 7. Hypertriglyceridemia in Knobloch patients. (A) Plasma
triglycerides were measured in blood samples collected from patients
with Knobloch syndrome (COL18A12/2) (open circles, n = 7), hetero-
zygous carriers (COL18A1+/2, closed squares, n = 6) and normal control
subjects (COL18A1+/+, closed circles, n = 6). Plasma triglycerides differed
by group (P=0.011) and the difference between Knobloch and normals
was significant (P,0.05) (B) Plasma Lpl levels were measured by
sandwich ELISA in previously frozen heparinized plasma collected from
fasting subjects with Knobloch syndrome (open circles), heterozygous
carriers (closed squares) and normal control family members (closed
circles). Plasma Lpl levels differed by group (P=0.001) and Knobloch
levels were reduced compared to heterozygotes (P,0.01) and
unaffected family members (P,0.01) (C) Activities levels of Lpl were
measured according to the assay described in Methods and converted
to units of (nanomoles) triglyceride hydrolyzed per hour per ml plasma.
Knobloch plasma contained reduced Lpl activity compared to
heterozygous carriers (P,0.05) and normal family members (P,0.01).
doi:10.1371/journal.pone.0013919.g007
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(i.e. mU activity) for each sample [62]. Levels of human Lpl were
determined by sandwich enzyme-linked immunosorbent assay
with a monoclonal anti-human Lpl antibody and polyclonal anti-
Lpl antibody (ALPCO Diagnostics, Salem, NH) according to
standard methods [63]. Levels of Lpl mass in plasma of mice was
determined by ELISA with immunopurified goat antibodies
against mouse Lpl [61].
Immunohistochemical localization of Lpl
Mice were perfused through the left ventricle with ,10 ml
phosphate-buffered saline at a rate of 2–3 ml/min after cutting the
inferior vena cava, then perfused with 10 ml 3% paraformaldehyde
in PBS. Excised tissues were post-fixed in 3% paraformaldehyde for
1 hr at room temperature, placed in 30% sucrose dissolved in PBS
overnight at 4uC and embedded the next day in OCT.
To detect LPL in mouse tissues, 10 mm-thick frozen sections
were prepared and incubated overnight with primary antibodies
[1:400 for the hamster anti-CD31 antibody (Millipore, Billerica,
Mass), 1:800 for the rat anti-GPIHBP1 antibody [64], 1:500 for
the rabbit anti-collagen type XVIII antibody (Cosmo Bio USA,
Carlsbad, CA), and 10 mg/ml for the goat anti–mouse LPL
antibody]. Secondary antibodies (Alexa488- or Alexa549-labeled
anti-hamster IgG, Alexa649-labeled anti-rat IgG, Alexa488- or
Alexa649-labeled anti-rabbit IgG, and Alexa555-labeled anti-goat
IgG) were used at a dilution of 1:200 and were incubated with
slides at room temperature for 1–2 h. Images were obtained by
confocal fluorescence microscopy with a Leica SP2 1P-FCS
microscope (Heidelberg, Germany). Images along the z-axis were
captured sequentially with a 636 objective and merged images
were generated with the Volocity 3D rendering software (version
4.4; PerkinElmer Improvision).
Human Subjects
Knobloch patients were recruited from a large family diagnosed
with a loss of function mutation affecting the expression of the
vascular isoform of COLA18 and characterized previously at the
Human Genome Center in Sa˜o Paulo, SP, Brazil [39]. Most
members of this large family live in a remote farming community
in Bahia State, Brazil and family members typically had similar
diets and shared living quarters. Approval for human studies and
informed consent of subjects were obtained from the Ethical
Committee of the Institute of Biosciences, University of Sa˜o Paulo
(Sa˜o Paulo, Brazil) and human studies were approved by the
University of California, San Diego, Human Subjects Protection
Program, #091434X. After obtaining signed informed consent, a
study investigator obtained a medical history and patients were
fasted for 4 hr after which a plasma sample was taken. Glucose
measurements were taken immediately with a glucometer. Study
participants with.200 mg/dl blood glucose, previously diagnosed
diabetes, heavy alcohol consumption (5 alcoholic drinks per day),
and tobacco use were excluded from the study (4 total). Plasma
triglyceride, cholesterol, and glucose levels from 7 homozygous
patients, 6 heterozygotes, and 6 age-matched normal subjects from
the family were measured using kits (Wako). A second affected
family member living in Sa˜o Paulo, Brazil along with 4 wild-type
controls living in the same household was tested.
Statistics
Statistical analyses were performed using PRISM (GraphPad
Software). All data are expressed as mean values 6 SD un-
less otherwise indicated. Comparisons between wild-type and
Col18a12/2 mice were determined using an unpaired Student’s
(two-tailed) t test. Knobloch, heterozygote carriers and unaffected
family members were compared by the non-parametric Kruskal-
Wallis test with Dunns post-test comparisons between all pairs of
genotypes. Significance was taken as P,0.05.
Supporting Information
Table S1 Knobloch patient data.
Found at: doi:10.1371/journal.pone.0013919.s001 (0.05 MB
DOC)
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